Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, February 14, 2023
[ Tue, Feb 14th 2023
] - WOPRAI
[ Tue, Feb 14th 2023
] - WOPRAI
[ Tue, Feb 14th 2023
] - WOPRAI
[ Tue, Feb 14th 2023
] - WOPRAI
[ Tue, Feb 14th 2023
] - WOPRAI
[ Tue, Feb 14th 2023
] - WOPRAI
[ Tue, Feb 14th 2023
] - WOPRAI
[ Tue, Feb 14th 2023
] - WOPRAI
[ Tue, Feb 14th 2023
] - WOPRAI
[ Tue, Feb 14th 2023
] - WOPRAI
[ Tue, Feb 14th 2023
] - WOPRAI
[ Tue, Feb 14th 2023
] - WOPRAI
[ Tue, Feb 14th 2023
] - WOPRAI
[ Tue, Feb 14th 2023
] - WOPRAI
[ Tue, Feb 14th 2023
] - WOPRAI
[ Tue, Feb 14th 2023
] - WOPRAI
[ Tue, Feb 14th 2023
] - WOPRAI
[ Tue, Feb 14th 2023
] - WOPRAI
[ Tue, Feb 14th 2023
] - WOPRAI
[ Tue, Feb 14th 2023
] - WOPRAI
[ Tue, Feb 14th 2023
] - WOPRAI
[ Tue, Feb 14th 2023
] - WOPRAI
[ Tue, Feb 14th 2023
] - WOPRAI
[ Tue, Feb 14th 2023
] - WOPRAI
[ Tue, Feb 14th 2023
] - WOPRAI
[ Tue, Feb 14th 2023
] - WOPRAI
[ Tue, Feb 14th 2023
] - WOPRAI
[ Tue, Feb 14th 2023
] - WOPRAI
[ Tue, Feb 14th 2023
] - WOPRAI
Mon, February 13, 2023
[ Mon, Feb 13th 2023
] - WOPRAI
Gregory Renza Maintained (ADCT) at Buy with Decreased Target to $12 on, Feb 13th, 2023
Gregory Renza of RBC Capital, Maintained "ADC Therapeutics SA" (ADCT) at Buy with Decreased Target from $18 to $12 on, Feb 13th, 2023.
Gregory has made no other calls on ADCT in the last 4 months.
There are 3 other peers that have a rating on ADCT. Out of the 3 peers that are also analyzing ADCT, 2 agree with Gregory's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Matthew Harrison of "Morgan Stanley" Maintained at Hold with Decreased Target to $5 on, Tuesday, January 24th, 2023
- Tazeen Ahmad of "B of A Securities" Downgraded from Strong Buy to Hold and Decreased Target to $7 on, Wednesday, November 9th, 2022
This is the rating of the analyst that currently disagrees with Gregory
- Robert Burns of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $20 on, Wednesday, January 4th, 2023
